Mexico Patent System

The LFPPI introduced several new IP categories that did not exist under the old LPI 1991: (1) Trade secrets (secretos industriales) — now explicitly defined and protectable under the LFPPI, with criminal penalties for misappropriation. Previously, trade secrets had limited civil-only protection; (2) Geographical Indications and Appellations of Origin — expanded protections for products like tequila, mezcal, and other regionally distinctive Mexican products; (3) Traditional knowledge and cultural expressions — provisions for protecting indigenous and traditional knowledge (acknowledging biodiversity and ethnoknowledge disputes that Mexico faced internationally). For patent purposes, the LFPPI maintained the 20-year patent term and 12-month grace period from the prior LPI, but added USMCA-mandated pharmaceutical patent linkage provisions not present in the 1991 law.

Under the LFPPI 2020, patent prosecution at IMPI involves: (1) Filing — online e-filing at impi.gob.mx; paper filing in Mexico City is also accepted; (2) Formalities examination — within 3 months of filing, IMPI checks completeness; (3) Request for substantive examination — applicant must request examination (no automatic examination); (4) Prior art search — IMPI conducts a search, often relying on EPO, USPTO, or WIPO search results where the applicant has previously filed; (5) Substantive examination — IMPI examines novelty, inventive step, industrial applicability, and Art. 19 LFPPI exclusions; (6) Office action — applicant has 2-month response period (extendable to 4 months); (7) Grant or rejection. Total timeline: typically 5–7 years from filing to grant for standard prosecution (significantly longer backlog than comparable economies). PPH with USPTO, EPO, and JPO can reduce this significantly.

Mexico's excluded subject matter under Art. 19 LFPPI includes: (1) Discoveries, scientific theories, and mathematical methods; (2) Schemes, rules, and methods for performing mental acts, games, or business activities; (3) Computer programs as such; (4) Methods of surgical, therapeutic, or diagnostic treatment of the human or animal body; (5) New plant varieties (covered separately under SNICS/UPOV); (6) Biological and genetic material as found in nature; (7) Essentially biological processes for the production of plants or animals. Software exclusion: Mexico excludes computer programs 'as such' — consistent with TRIPS. Software with technical application (embedded systems, industrial control, telecommunications equipment) may qualify as a patentable invention if it solves a technical problem and is not merely an abstract method.

The USMCA (United States-Mexico-Canada Agreement, effective July 1, 2020 — known as T-MEC in Mexico) significantly upgraded Mexico's pharmaceutical IP obligations from what existed under NAFTA 1994. The three main USMCA changes for pharmaceutical patents are: (1) Patent linkage (Art. 20.38): Mexico was required to create a pharmaceutical patent linkage system — linking COFEPRIS (Mexico's drug regulator) generic drug approvals to the patent status of the innovator drug. Before USMCA, Mexico had no formal patent linkage. Under the new system, generic applicants must notify innovator patent holders when seeking marketing approval, and patent holders can oppose approval based on listed patents. Mexico is implementing this through COFEPRIS regulation; (2) Data exclusivity for NCEs: USMCA requires at least 5 years of data exclusivity for new chemical entities — protecting clinical trial data submitted to COFEPRIS from reliance by generic applicants, even without a patent. Before USMCA, Mexico's data exclusivity framework was weak and inconsistently applied; (3) Biologics data exclusivity: USMCA requires at least 5 years of data protection for biologic drugs. Before USMCA, Mexico had no specific biologics exclusivity framework. The practical impact for innovator pharmaceutical and biotech companies: patents in Mexico are now reinforced by COFEPRIS patent linkage and NCE/biologics data exclusivity — creating a multi-layered protection system similar to (though less extensive than) the US Hatch-Waxman and BPCIA frameworks. Companies launching branded drugs in Mexico should ensure their patents are registered with COFEPRIS under the linkage system.

A Mexican utility model (Modelo de Utilidad) is a form of IP protection for functional objects, devices, mechanisms, and tools that provides 10 years of protection with a lower inventive threshold than a full invention patent. The key differences from a Mexican invention patent: (1) No inventive step required: a utility model only requires novelty and industrial applicability. You do not need to show that the improvement was non-obvious. This makes it easier to obtain and harder to invalidate on non-obviousness grounds; (2) Covers only objects/devices — NOT processes: utility models in Mexico protect functional three-dimensional objects. You cannot use a utility model for a process, method, chemical composition, or software; (3) 10-year term vs 20-year for invention patents: shorter protection in exchange for easier registration; (4) Cannot protect the same innovation with both: if you file a utility model, you cannot also file an invention patent for the same invention. Use utility models when: (a) You have an incremental improvement to an existing physical product that is novel but may not clear the inventive step bar for a full patent; (b) You need fast protection — utility model examination at IMPI is typically faster than invention patent examination; (c) Your product life cycle is less than 10 years (if you'll stop making the product in 8 years, a 10-year utility model term is sufficient); (d) You are manufacturing in Mexico and want domestic protection for manufacturing innovations that are product improvements. Utility models are particularly well-suited for Mexico's manufacturing sector — automotive parts, electronics, medical devices, household goods — where incremental functional improvements to products are common and the 10-year term aligns with product cycle timescales.

Yes — Mexico has a 12-month grace period for patent filing under Article 47 of the Ley Federal de Protección a la Propiedad Industrial (LFPPI 2020). If the inventor (or any person who obtained the information directly or indirectly from the inventor) discloses the invention before the patent filing date, that disclosure does not constitute prior art against the inventor's own patent application, provided the patent application is filed within 12 months of the disclosure. Important limitations: (1) The grace period applies only to the inventor's own disclosures, or disclosures made by someone who learned of the invention from the inventor. Third-party disclosures (unrelated to the inventor) are still prior art against the application; (2) The 12-month window applies to IMPI national filings and PCT national phase entries designating Mexico. A PCT application filed within 12 months of the disclosure, which then enters the Mexican national phase within 30 months, would preserve the grace period benefit; (3) Mexico's grace period only protects you against your own prior disclosure being cited as prior art against your Mexican application — it does NOT protect you against European Patent (EPO) applications or other jurisdictions with absolute novelty (no grace period). If you disclosed your invention and then filed in Mexico within 12 months but didn't file an EP application, the disclosure is prior art against the EP application. Practical rule: Mexico's 12-month grace period provides meaningful safety margin for inventors who accidentally disclosed before filing, but it should not be relied upon as a routine strategy. File before any disclosure when possible to preserve global patent rights.

Standard patent prosecution at IMPI (Instituto Mexicano de la Propiedad Industrial) takes approximately 5–8 years from filing to grant — one of the longer prosecution timelines among major economies. However, several acceleration mechanisms can reduce this significantly: (1) Patent Prosecution Highway (PPH): Mexico has PPH agreements with the USPTO, EPO, JPO, KIPO, and other major offices. If your application has been allowed (all claims found allowable) at one of these offices, you can request PPH at IMPI. PPH applications typically receive IMPI examination within 3–12 months — dramatically faster than the standard 5–8 year timeline. The USPTO-IMPI PPH is particularly useful for US companies: if your US application receives a notice of allowance, you can request PPH at IMPI and potentially receive a Mexican patent within 12–24 months total. (2) PCT national phase with positive international search report: if your PCT application received a positive International Search Report and Written Opinion, IMPI often uses this as the basis for its examination, accelerating the process. (3) Divisional applications and continuations: for complex cases, filing divisional applications at IMPI after restriction requirements from the examiner can segment the prosecution and resolve each divisional faster than the parent. Why is IMPI slow? IMPI has historically faced large application backlogs. The LFPPI 2020 and associated IMPI internal reforms have been aimed at reducing backlogs, but 5–8 years remains realistic for standard (non-PPH) prosecution. For companies entering the Mexican market, this means filing early (as early as the priority date) and using PPH aggressively to obtain grant before product launch if possible.

Nearshoring to Mexico (relocating manufacturing from Asia, particularly China, to Mexico) creates specific IP considerations that companies should address before and during the transition: (1) Trade secret protection: LFPPI 2020 significantly strengthened Mexico's trade secret framework — including criminal penalties for misappropriation. Manufacturing processes, formulas, supplier lists, and operational know-how can be protected as trade secrets under Mexico's Secreto Industrial provisions. Practical steps: implement confidentiality agreements with Mexican employees and contractors under Mexican law (NDAs must comply with Mexican law to be enforceable), mark materials as confidential, and implement access controls for sensitive processes; (2) Employment and invention assignments: Mexican law does not have a clear automatic employer-ownership rule for employee inventions equivalent to the US PIIA framework or France's mission invention doctrine. Mexican employment contracts should explicitly assign IP rights in inventions developed during employment using company resources. The assignment should be written, signed, and clear about scope — inventions made using company time, facilities, or information are assignable by contract; (3) Supplier contracts and IP ownership: if a Mexican manufacturer or contract manufacturer develops improvements to your product or process during the manufacturing relationship, who owns those improvements? Without explicit contractual provisions, this is ambiguous under Mexican law. Manufacturing agreements should explicitly address: who owns process improvements; whether the manufacturer has rights to reverse-engineer for other customers; and IP warranties from the manufacturer; (4) IMMEX/maquiladora programs: companies using IMMEX programs (temporary import of raw materials for export of finished goods) must ensure that IP licensing between the US parent and Mexican manufacturing subsidiary complies with IMPI licensing registration requirements and Mexican transfer pricing rules. Patent license agreements, technology transfer agreements, and know-how licenses between related parties must be registered with IMPI to be enforceable against third parties; (5) Customs recordation: to stop infringing products at Mexican Customs (Aduana), patent owners can record their IP rights with IMPI and through Mexican Customs procedures — important for protecting against counterfeit products that might be imported through Mexico.